We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Smoking Treatment of Prisoners (STOP)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00110630
First Posted: May 11, 2005
Last Update Posted: January 12, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
GlaxoSmithKline
Information provided by:
National Institute on Drug Abuse (NIDA)
May 11, 2005
May 11, 2005
January 12, 2017
June 2005
September 2007   (Final data collection date for primary outcome measure)
smoking cessation
Not Provided
Complete list of historical versions of study NCT00110630 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Smoking Treatment of Prisoners
Smoking Treatment of Prisoners: Project "STOP"
The purpose of this study is to determine the efficacy of a 10-week smoking cessation therapy combined with NicoDerm CQ for smoking cessation among female prisoners.
This is a randomized controlled trial utilizing a wait-list control group to examine 10-week group therapy and nicotine replacement compared to wait-list for smoking cessation among female prisoners.
Interventional
Phase 3
Allocation: Randomized
Masking: None (Open Label)
Primary Purpose: Treatment
  • Tobacco Use Cessation
  • Tobacco Use Disorder
Behavioral: 10-week smoking cessation group therapy combined with NicoDerm CQ
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
250
September 2007
September 2007   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • 1) current smoker and (2) seeking group treatment to quit smoking.

Exclusion Criteria:

  • (1) non-english speaking, (2) housed in segregation, (3) presence of active, severe mental illness as defined by active psychosis, manic episode, or imminently suicidal/homicidal, (4) mental retardation such that they cannot provide informed consent, and (5) due to be released or transferred to another facility within the next year.
Sexes Eligible for Study: Female
18 Years to 100 Years   (Adult, Senior)
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00110630
NIDA-15774-2
K23-15774-2
Yes
Not Provided
Not Provided
Karen Cropsey, Univeristy of Alabama at Birmingham
National Institute on Drug Abuse (NIDA)
GlaxoSmithKline
Principal Investigator: Karen Cropsey, Ph.D. Virginia Commonwealth University
National Institute on Drug Abuse (NIDA)
September 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP